1. Home
  2. IART vs CGEM Comparison

IART vs CGEM Comparison

Compare IART & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra LifeSciences Holdings Corporation

IART

Integra LifeSciences Holdings Corporation

HOLD

Current Price

$9.32

Market Cap

696.8M

Sector

Health Care

ML Signal

HOLD

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

HOLD

Current Price

$14.41

Market Cap

794.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IART
CGEM
Founded
1989
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
696.8M
794.7M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
IART
CGEM
Price
$9.32
$14.41
Analyst Decision
Hold
Strong Buy
Analyst Count
7
9
Target Price
$14.50
$30.11
AVG Volume (30 Days)
769.4K
749.6K
Earning Date
05-04-2026
03-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.45
N/A
Revenue Next Year
$3.40
$79.85
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.70
$5.68
52 Week High
$22.27
$16.74

Technical Indicators

Market Signals
Indicator
IART
CGEM
Relative Strength Index (RSI) 38.51 56.33
Support Level N/A $11.43
Resistance Level $14.14 $16.74
Average True Range (ATR) 0.42 0.86
MACD 0.06 -0.18
Stochastic Oscillator 58.33 52.27

Price Performance

Historical Comparison
IART
CGEM

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and Tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales. The company operates in United States, Europe, Asia Pacific, and Rest of the World.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: